Navigation Links
Hepatitis Rates Soar Among IV Drug Users, Study Finds
Date:7/27/2011

WEDNESDAY, July 27 (HealthDay News) -- About 10 million injection drug users worldwide have hepatitis C, and 1.3 million have hepatitis B, a new study reports.

Hepatitis can lead to cirrhosis, liver failure and liver cancer.

Researchers analyzed international data and found that rates of hepatitis C infection among injection drug users (IDUs) were 60 to 80 percent in 25 countries and greater than 80 percent in 12 other countries.

These countries included Spain (80 percent), Norway (76 percent), Germany (75 percent), France (74 percent), United States (73 percent), China (67 percent), Canada (64 percent), Italy (81 percent), Portugal (83 percent), Pakistan (84 percent), the Netherlands (86 percent), Thailand (90 percent) and Mexico (97 percent).

Lower rates were seen in New Zealand (52 percent), Australia (55 percent) and the United Kingdom (50 percent), the researchers noted.

The countries believed to have the largest number of IDUs infected with hepatitis C virus (HCV) are China (1.6 million), the United States (1.5 million) and Russia (1.3 million), the investigators found.

Rates of hepatitis B infection were 5 to 10 percent in 21 countries and more than 10 percent in 10 countries. The highest rates were in Vietnam (20 percent), Estonia (19 percent), Saudi Arabia (18 percent) and Taiwan (17 percent). The United Kingdom had the highest rate in Western Europe at 9 percent. The rate in the United States was 12 percent.

The study, released to coincide with World Hepatitis Day, is published online July 28 in The Lancet.

"The public-health response to blood-borne virus transmission in IDUs has mainly centered on HIV. Maintenance and strengthening of the response to HIV in IDUs remains crucial, but the significance of viral hepatitis needs to receive greater attention than it does at present," Paul Nelson, from the National Drug and Alcohol Research Centre at the University of New South Wales in Sydney, and colleagues wrote.

"Efforts to prevent, treat, and reduce harms related to liver disease in IDUs are essential -- especially in situations in which HIV has successfully been prevented or managed -- because the large numbers of IDUs infected with HCV and significant morbidity resulting from this infection mean that the health and economic costs of HCV transmitted by injected drug use might be as high as (or higher than) those of HIV," the authors added.

"Nonetheless, HCV treatment is underused. Part of the reason for this neglect is the high cost, which will remain a substantial barrier to increasing of treatment coverage in low-resource settings until costs are reduced," the researchers concluded.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about viral hepatitis.

-- Robert Preidt

SOURCE: The Lancet, news release, July 27, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. INFORMS study: OR models of hepatitis B prove decisive in treating millions in US, China
2. Hepatitis B vaccination for health care students lags behind recommendations
3. Hepatitis C is transmitted by unprotected sex between HIV-infected men
4. P7 protein resistance mutations identified; represent drug targets for hepatitis C virus
5. Stepped-up vaccine series for hepatitis B is effective during pregnancy
6. New Drug Effectively Treats Hepatitis C
7. NEJM study: New drug represents breakthrough in treatment of hepatitis C
8. Noninvasive liver tests may predict hepatitis C patient survival
9. Analysis finds mortality from all causes higher among hepatitis C-infected
10. Scientists create humanized mouse model for hepatitis C
11. Coffee drinking improves hepatitis C treatment response
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hepatitis Rates Soar Among IV Drug Users, Study Finds
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers of the wildly ... Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. The Olympia top ... and in less than a year was able to turn professional, participating in the ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities and individuals ... have been developed for use by nutrition educators and influencers within the ...
(Date:1/22/2017)... Raton, FL (PRWEB) , ... January 22, 2017 , ... ... to customers across the world, recently met with big-name retail buyers at the January ... scientific evidence of efficacy and uses the utmost safety standards in all of its ...
(Date:1/21/2017)... , ... January 21, 2017 , ... "ProDOF is the perfect set of tools for ... another subject in a scene," said Christina Austin - CEO of Pixel Film Studios. ... Easily create the illusion of a DSLR racking focus from one area into the ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... medical office in Petaluma, located at 167 Lynch Creek Way. The Petaluma office ... SRO sports medicine and rehabilitation services and on-site x-ray services. Two multi-specialist ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... -- ResMed (NYSE: RMD ), BMC ( Beijing, ... ) today announced they have agreed on a global settlement ... permitted to sell their existing products in exchange for royalty payments ... 3B to close the Florida litigation between ... liability or wrongdoing by any party. The five-year ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... Of Administration, End User - Forecast to 2025" report to ... The ... CAGR of around 7.8% over the next decade to reach approximately ... the global markets for Advanced Drug Delivery across all the given ...
(Date:1/20/2017)... , Jan. 20, 2017  Ethicon Endo-Surgery, ... Megadyne Medical Products, Inc., a privately held ... markets electrosurgical tools used in operating rooms ... of Ethicon,s* advanced energy devices with Megadyne,s ... major step forward in Ethicon,s goal to ...
Breaking Medicine Technology: